Luke Greenwalt, MBA, on the Current Market Conditions for New Drug Launches | Asembia's AXS25 Summit
The vice president and lead of IQVIA's Market Access Center of Excellence says fewer drugs are hitting the $100 million mark during their first year on the market than in the past.
In this segment of an interview with Managed Healthcare Executive (MHE) conducted before his talk at 2025 Asembia's AXS25 Summit in Las Vegas, Luke Greenwalt discusses new drug launches. Greenwalt, vice president and lead of the Market Access Center of Excellence at IQVIA and a member of the MHE editorial advisory board, noted that in the past five years, fewer drugs are achieving $100 million of sales in their first year than in the previous five years. On the other hand, more newly launched drugs have hit the $1 billion mark in their inaugural year recently. "We're seeing very, very successful products come into the market, such as RSV [respiratory syncytial virus] vaccines and the GLP-1s [glucagon-like peptide 1s] for obesity and diabetes treatment." Greenwalt noted, though, that there is greater payer control than ever before.
Healthcare hasn't been a priority of the second Trump administration so far, panelists at the Asembia agreed. Medicaid may loom large, though, as the administration and congressional Republicans look for ways to slash government spending as a way of offsetting major tax cuts.
Read More
